{"id":60125,"date":"2026-03-20T12:35:32","date_gmt":"2026-03-20T04:35:32","guid":{"rendered":"https:\/\/flcube.com\/?p=60125"},"modified":"2026-03-20T12:35:33","modified_gmt":"2026-03-20T04:35:33","slug":"pfizer-reports-positive-talapro-3-results-talzenna-xtandi-combo-hits-primary-endpoint-in-hrr-mutated-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60125","title":{"rendered":"Pfizer Reports Positive TALAPRO-3 Results \u2013 TALZENNA\/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer"},"content":{"rendered":"\n

Pfizer Inc.<\/strong> (NYSE: PFE<\/a>) announced positive topline results<\/strong> from the Phase 3 TALAPRO-3 study<\/strong>, demonstrating that TALZENNA (talazoparib)<\/strong> plus XTANDI (enzalutamide)<\/strong> achieved statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS)<\/strong> in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC\/mHSPC)<\/strong>, with efficacy markedly exceeding the pre-specified target and consistent benefit across BRCA and non-BRCA HRR alterations<\/strong>.<\/p>\n\n\n\n

Clinical Milestone \u2013 TALAPRO-3 Phase 3<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Study<\/strong><\/td>TALAPRO-3 (Phase 3)<\/td><\/tr>
Investigational Regimen<\/strong><\/td>TALZENNA (talazoparib) + XTANDI (enzalutamide)<\/td><\/tr>
Control Arm<\/strong><\/td>Placebo + XTANDI<\/td><\/tr>
Patient Population<\/strong><\/td>HRR gene-mutated mCSPC\/mHSPC (metastatic castration\/hormone-sensitive prostate cancer)<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Radiographic progression-free survival (rPFS)<\/td><\/tr>
Result<\/strong><\/td>Statistically significant rPFS improvement<\/strong>; markedly exceeded pre-specified HR 0.63<\/td><\/tr>
Progression Status<\/strong><\/td>Majority of patients progression-free at analysis<\/td><\/tr>
HRR Subgroups<\/strong><\/td>Consistent efficacy in BRCA and non-BRCA HRR alterations<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Secondary Endpoints & Safety<\/h2>\n\n\n\n
Endpoint<\/th>Result<\/th>Clinical Significance<\/th><\/tr><\/thead>
Overall Survival (OS)<\/strong><\/td>Strong trend toward improvement<\/strong><\/td>Key secondary endpoint; mature data pending<\/td><\/tr>
Overall Response Rate (ORR)<\/strong><\/td>Benefit observed<\/td>Tumor shrinkage efficacy<\/td><\/tr>
Duration of Response (DoR)<\/strong><\/td>Benefit observed<\/td>Sustained anti-tumor activity<\/td><\/tr>
Time to PSA Progression<\/strong><\/td>Benefit observed<\/td>Biochemical disease control<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with known TALZENNA + XTANDI safety; no new safety signals<\/strong><\/td>Predictable tolerability supports clinical adoption<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regulatory & Commercial Context<\/h2>\n\n\n\n
Dimension<\/th>Current Status<\/th>Strategic Implication<\/th><\/tr><\/thead>
Approved Indications<\/strong><\/td>60 countries<\/strong> including US (HRR-mutated mCRPC) and EU (mCRPC, chemo-ineligible)<\/td>Established safety\/efficacy profile de-risks mCSPC label expansion<\/td><\/tr>
TALAPRO-3 Expansion<\/strong><\/td>mCSPC\/mHSPC (earlier-line metastatic setting)<\/td>Addresses larger patient population vs. mCRPC; potential for first-line PARP+ARPI combination standard<\/td><\/tr>
HRR Biomarker Strategy<\/strong><\/td>BRCA + non-BRCA HRR genes (ATM, CHEK2, PALB2, etc.)<\/td>Broad genomics-based indication vs. BRCA-only competitors (Lynparza)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n